SCI & TECH● LOW1h ago · Oct 23, 2026, 2:44 PM
Alnylam sees promising early-stage data for Huntington's asset brezosiran
Seeking Alpha Tech · global
Alnylam has reported encouraging early-stage trial data for brezosiran, a potential treatment for Huntington's disease, which could signify progress in addressing the condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH21m agoCognitive surrender: Artificial intelligence’s threat to democracyThe HillSCI & TECH45m agoTikTok U.S. hunts for multiple gigawatts of computing capacity, sources tell CNBCCNBCSCI & TECH52m agoNew agenda need of the hour for India’s space ecosystem: IIST V-C Dipankar BanerjeeThe HinduSCI & TECH1h agoRocket debris hitting US homeland is ‘embarrassing’ for China, says astronomerSouth China Morning Post